Sign in

CIK 0001919246 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Pelthos Therapeutics Inc.

Sign in to watch
Ticker
PTHS
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
NV
Entity type
operating
EIN
863335449
Phone
919-908-2422
Business address
4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703
Former names
Channel Therapeutics Corp, Chromocell Therapeutics Corp
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$44,939
in 3 filings, $45K under 10b5-1 plans

Net −$44,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Greenleaf Peter −$17K Director sold 3% of stake
  2. Pauls Matthew −$17K Director sold 5% of stake
  3. Friedberg Ezra M −$12K Director sold <1% of stake
Date Insider Transaction Shares Price Value Owned after
2026-10-02 Pauls Matthew Director Sale 10b5-1 −786 $21.00 $17K 13,578
2026-07-02 Pauls Matthew Director Sale 10b5-1 −692 $26.00 $18K 14,458
2026-07-02 Pauls Matthew Director Sale 10b5-1 −94 $27.36 $3K 14,364
2026-04-02 Pauls Matthew Director Sale 10b5-1 −415 $20.52 $9K 15,521
2026-04-02 Pauls Matthew Director Sale 10b5-1 −371 $21.36 $8K 15,150
2025-12-10 Pauls Matthew Director Gift −9,542 1,074
2025-10-02 Pauls Matthew Director Option exercise +2,123 10,616
2025-10-02 Pauls Matthew Director Option exercise · Restricted Stock Units −2,123 14,862
2025-07-02 Pauls Matthew Director Grant or award +25,478 25,478
2025-07-02 Pauls Matthew Director Option exercise +8,493 8,493
2025-07-02 Pauls Matthew Director Option exercise · Restricted Stock Units −8,493 16,985
2025-07-02 Pauls Matthew Director Grant or award · Restricted Stock Units +25,478 25,478
2025-07-02 Pauls Matthew Director Grant or award · Stock Option +77,640 77,640

Page 1 of 1 · 13 trades